ClinicalTrials.gg
CompletedNCT07476664AOCUpdated Mar 17, 2026

Acute Oroantral Communication Closure: Resorbable Collagen Membrane vs. Buccal Advancement Flap Outcomes

An interventional study of Resorbable collagen membrane OAC closure and Buccal advancement flap OAC closure in Oroantral Communication, Acute Oroantral Communication and Oroantral Fistula, sponsored by Medical University of Silesia. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled May 2021, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Oroantral communication (OAC) is an abnormal opening between the oral cavity and the maxillary sinus that may occur after extraction of posterior maxillary teeth. If not treated promptly, it can lead to sinus contamination, chronic infection, and development of an oroantral fistula requiring more complex surgical management. The standard surgical treatment is closure with a buccal advancement flap (Rehrmann technique). However, this method may reduce vestibular depth, displace the mucogingival junction, and decrease the width of keratinized gingiva.

This prospective clinical study compares two surgical approaches for closure of acute OAC diagnosed within 24 hours after tooth extraction: placement of a resorbable collagen membrane beneath the mucosa versus the conventional buccal advancement flap. Clinical and radiographic parameters related to soft tissue architecture, postoperative recovery, and bone healing are evaluated during a 90-day follow-up period.

Read the detailed description

Oroantral communication (OAC) is a pathological connection between the oral cavity and the maxillary sinus most commonly occurring after extraction of posterior maxillary teeth. The close anatomical relationship between the sinus floor and the roots of maxillary molars and premolars increases the risk of perforation of the Schneiderian membrane during dental extraction. If an OAC is not diagnosed and treated promptly, microbial contamination of the sinus may occur, potentially resulting in chronic maxillary sinusitis and epithelialization of the tract with formation of an oroantral fistula. Early closure of acute defects within 24-48 hours is therefore generally recommended.

The buccal advancement flap described by Rehrmann is the most frequently used surgical technique for closure of acute OAC because of its technical simplicity and predictable closure of the defect. Nevertheless, advancement of the buccal mucoperiosteal flap may alter local soft tissue anatomy, including reduction of vestibular depth, displacement of the mucogingival junction, and loss of keratinized gingiva. These anatomical changes may affect oral hygiene and may complicate future prosthetic or implant therapy.

Biomaterial-based techniques that preserve soft tissue architecture represent a potential alternative approach. Resorbable collagen membranes are widely used in guided tissue regeneration and guided bone regeneration due to their biocompatibility, clot stabilization properties, and barrier function. Heterologous collagen membranes, such as Creos Xenoprotect, are designed to integrate with surrounding tissues and gradually resorb without the need for surgical removal. Their use for closure of acute OAC has been described in clinical reports; however, comparative clinical data against conventional flap techniques remain limited.

The present study is designed as a prospective, non-randomized comparative clinical investigation evaluating two surgical methods for closure of acute oroantral communications diagnosed within 24 hours after extraction of posterior maxillary teeth. Adult patients presenting with clinically and radiographically confirmed OAC are screened for eligibility and allocated to treatment according to the predefined clinical protocol.

In the experimental group, closure of the communication is performed using a resorbable heterogeneous collagen membrane (Creos Xenoprotect) placed in a submucosal position to cover the defect. Limited mucoperiosteal elevation is performed as necessary, and the membrane is stabilized using sutures to achieve tension-free closure.

In the control group, closure is performed using the conventional Rehrmann buccal advancement flap. After preparation of the extraction socket, a trapezoidal mucoperiosteal flap with vertical releasing incisions is elevated, mobilized using periosteal releasing incisions, and advanced coronally to achieve primary closure of the defect.

The size of the oroantral communication is measured clinically using a calibrated periodontal probe and confirmed with limited-field cone-beam computed tomography (CBCT). Standardized perioperative management is applied in both groups, including socket debridement, smoothing of bony margins, sinus precautions, and scheduled postoperative follow-up.

02

Conditions studied

  • Oroantral Communication
  • Acute Oroantral Communication
  • Oroantral Fistula
  • Post-extraction Maxillary Sinus Communication

Keywords

  • oroantral communication
  • acute OAC
  • buccal advancement flap
  • Rehrmann flap
  • oral surgery
  • CBCT bone density
  • vestibular depth preservation
03

In context

Lead sponsor

Medical University of Silesia is the lead sponsor of 117 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Acute oroantral communication diagnosed within 24 hours after extraction of a maxillary posterior tooth
  • General health status permitting outpatient dental surgery
  • Indication for single-tooth extraction in the posterior maxilla
  • Systemic conditions not contraindicating minor oral surgery
  • Ability and willingness to attend scheduled follow-up visits
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Oroantral communication present for more than 24 hours
  • Chronic inflammatory disease of the maxillary sinus
  • History of head and neck neoplastic disease or its treatment
  • Pregnancy
  • Systemic diseases preventing outpatient surgical treatment
  • Blood disorders or coagulation abnormalities
  • Ongoing anticoagulant therapy
  • therapy
  • Age under 18 years
  • History of multiple previous surgical procedures in the study area
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Resorbable Collagen Membrane Closure

    Participants with acute oroantral communication diagnosed within 24 hours after extraction underwent minimally invasive closure using a resorbable heterogeneous collagen membrane (Creos Xenoprotect). After socket debridement and smoothing of sharp bony margins, the membrane was trimmed and inserted in a submucosal position to fully cover the defect. Limited mucoperiosteal elevation was performed without vertical releasing incisions. The membrane was stabilized with horizontal mattress sutures and allowed to integrate and resorb spontaneously. Standardized postoperative care, antibiotics, and follow-up were provided.

    Procedure: Resorbable collagen membrane OAC closure

  • Active comparator
    Buccal Advancement Flap (Rehrmann)

    Participants with acute oroantral communication diagnosed within 24 hours after extraction underwent closure using the conventional Rehrmann buccal advancement flap. Following socket debridement and smoothing of bony margins, a trapezoidal full-thickness mucoperiosteal flap with vertical releasing incisions was elevated, mobilized with periosteal releasing incisions, and advanced coronally to achieve tension-free primary closure. Standardized postoperative care, antibiotics, and follow-up identical to the experimental arm were applied.

    Procedure: Buccal advancement flap OAC closure

Interventions

  • ProcedureResorbable collagen membrane OAC closure

    Minimally invasive closure of acute oroantral communication using a resorbable heterogeneous collagen membrane placed in a submucosal position. After extraction socket debridement and smoothing of sharp bony margins, the membrane was trimmed to overlap the defect and inserted beneath the mucosa to fully cover the communication. Limited mucoperiosteal elevation was performed without vertical releasing incisions. The membrane was stabilized using horizontal mattress sutures to achieve tension-free coverage and was left to integrate and resorb spontaneously. Standardized postoperative antibiotics, sinus precautions, and follow-up visits were applied.

    Also known as: Creos Xenoprotect, Collagen membrane closure, Submucosal membrane technique

  • ProcedureBuccal advancement flap OAC closure

    Conventional surgical closure of acute oroantral communication using a coronally advanced buccal mucoperiosteal flap. Following socket debridement and smoothing of bony margins, a trapezoidal full-thickness flap with vertical releasing incisions was elevated. Periosteal releasing incisions were performed to allow tension-free coronal advancement of the flap over the defect. Primary closure was achieved with interrupted sutures. Postoperative management, including antibiotics, sinus precautions, and scheduled follow-up, was standardized across study groups.

    Also known as: Rehrmann flap, Rehrmann technique, Buccal advancement flap

06

What researchers measure

Primary outcomes

  1. Change in vestibular depth from baseline to 90 days

    The primary outcome was the change in oral vestibular depth at the surgical site, measured in millimeters using a calibrated WHO periodontal probe. Measurements were obtained at baseline (day 0) and during follow-up visits. The endpoint reflects preservation of soft tissue architecture after oroantral communication closure. Greater preservation (smaller reduction from baseline) indicates a more favorable clinical outcome for future prosthetic or implant rehabilitation.

    Time frame: Baseline (day 0) to 90 days postoperatively

Secondary outcomes

  1. Change in keratinized gingiva width

    Width of keratinized gingiva at the surgical site measured in millimeters with a calibrated WHO periodontal probe at baseline and follow-up visits. The outcome assesses preservation of keratinized tissue after oroantral communication closure. Greater preservation indicates a more favorable soft tissue result for long-term oral hygiene and prosthetic planning.

    Time frame: Baseline (day 0) to 90 days postoperatively

  2. Change in alveolar socket width

    Buccopalatal width of the post-extraction alveolar socket measured clinically and radiographically at predefined time points. This parameter evaluates dimensional stability of the alveolar ridge following closure of oroantral communication. Smaller reduction from baseline indicates better preservation of ridge architecture.

    Time frame: Baseline (day 0) to 90 days postoperatively

  3. Postoperative pain intensity (VAS)

    Patient-reported pain assessed using a 100 mm Visual Analogue Scale (VAS), where 0 indicates no pain and 100 indicates worst imaginable pain. Patients marked their pain level at each follow-up visit. Lower scores indicate better postoperative comfort.

    Time frame: Postoperative days 1, 7, and 14

  4. Incidence of postoperative complications

    Occurrence of adverse postoperative events including swelling, hematoma, epistaxis, wound dehiscence, persistent oroantral communication, fistula formation, or clinical signs of sinusitis. Events were recorded during scheduled follow-up visits.

    Time frame: Up to 90 days postoperatively

07

Study locations

1 site
  • University Dental Clinic of the Silesian Medical University in Katowice
    Bytom, Poland
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Dec 2025, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 17, 2026
StartActual
May 1, 2021
Primary completionActual
Dec 1, 2025
CompletionActual
Dec 1, 2025
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476664
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
May 1, 2021
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025
Last update
Mar 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion